Battling the second wave of Covid-19, South Africa is expected to receive a million doses of Covishield by the end of January and another 5 lakh in February of this year.
File photo of SII's coronavirus vaccine 'Covishield' (Photo Credits: PTI)
South Africa has granted approval to Pune-based SII to supply doses of its coronavirus vaccine 'Covishield' to the country. The decision was announced by South Africa's Health Minister Zweli Mkhize on Saturday.
The South African Health Products Regulatory Authority (SAHPRA) has granted approval to the Serum Institute of India to supply Covishield, Minister Mkhize said. He went on to add, "We will, in the next coming days, engage with the public in order to give an update on the progress of the first batch of the vaccines that we committed would be received in the first quarter."
Battling the second wave of Covid-19, South Africa is expected to receive a million doses of Covishield by the end of January and another 5 lakh in February of this year. The country which is also staring at a new mutant variant of the coronavirus has decided to vaccinate healthcare workers in the first stage.
"At this stage, we would like to assure South Africans that all is on track. We are working closely with all relevant stakeholders to ensure a smooth implementation of the vaccine roll-out programme," news agency PTI quoted South Africa's Health Minister Zweli Mkhize as saying.
The world's largest drug manufacturer, Pune-based SII is producing Covishield developed jointly by the University of Oxford and AstraZeneca. Earlier this month, the Government of India approved the commercial supply of coronavirus vaccines. Brazil and Morocco have already received doses of Covid-19 vaccines supplied by India.
Source - India Today
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.